UTHR
United Therapeutics Corporation
NASDAQ: UTHR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$571.07
+0.34% today
Updated 2026-04-29
Market cap
$25.03B
P/E ratio
20.48
P/S ratio
7.86x
EPS (TTM)
$27.89
Dividend yield
—
52W range
$272 – $608
Volume
0.6M
WallStSmart proprietary scores
67
out of 100
Grade: B
Buy
Investment rating
7.3
Growth
B+7.8
Quality
B+9.0
Profitability
A+5.3
Valuation
C+5/9
Piotroski F-Score
Moderate
7.3
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$644.62
+12.88%
12-Month target
$542.84
-4.94%
Intrinsic (DCF)
$521.18
Margin of safety
+8.70%
1 Strong Buy9 Buy4 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 7.30 — safe zone
+ Profit margin 41.90% — above average
+ Free cash flow $173.30M — positive
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $1.94B | $2.33B | $2.88B | $3.18B | $3.18B | $3.4B |
| Net income | $727.30M | $984.80M | $1.20B | $1.33B | $364.30M | — |
| EPS | — | — | — | — | $27.89 | $29.87 |
| Free cash flow | $663.70M | $747.60M | $1.08B | $1.04B | $173.30M | — |
| Profit margin | 37.56% | 42.31% | 41.53% | 41.94% | 41.90% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-17 | PATUSKY, CHRISTOPHER | Sale | 1,000 | — |
| 2026-04-17 | PATUSKY, CHRISTOPHER | Buy | 1,000 | $101.80 |
| 2026-04-16 | ROTHBLATT, MARTINE A | Sale | 9,500 | — |
Peer comparison
Smart narrative
United Therapeutics Corporation trades at $571.07. representing a P/E of 20.48x trailing earnings. Our Smart Value Score of 67/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 7.30, it sits in the safe zone. TTM revenue stands at $3.18B. with profit margins at 41.90%. Our DCF model estimates intrinsic value at $521.18.
Frequently asked questions
What is United Therapeutics Corporation's stock price?
United Therapeutics Corporation (UTHR) trades at $571.07.
Is United Therapeutics Corporation overvalued?
Smart Value Score 67/100 (Grade B, Buy). DCF value $521.18.
What is the price target of United Therapeutics Corporation (UTHR)?
The analyst target price is $644.62, representing +12.9% upside from the current price of $571.07.
What is the intrinsic value of United Therapeutics Corporation (UTHR)?
Based on our DCF model, intrinsic value is $521.18, a +8.7% margin of safety versus $571.07.
What is the future stock price of UTHR by 2030?
Our research-backed model estimates United Therapeutics Corporation could reach $1,637.95 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is United Therapeutics Corporation's revenue?
TTM revenue is $3.18B.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
7.30 — safe zone.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio7.86x
ROE19.70%
Beta0.75
50D MA$538.47
200D MA$451.17
Shares out0.04B
Float0.04B
Short ratio—
Avg volume0.6M
Performance
1 week+0.69%
1 month+0.14%
3 months+21.64%
YTD+17.20%
1 year—
3 years—
5 years—